Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials
- 5 December 2002
- Vol. 21 (15), 1650-1657
- https://doi.org/10.1016/s0264-410x(02)00701-6
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Current developments in malaria transmission-blocking vaccinesExpert Opinion on Biological Therapy, 2001
- Plasmodium falciparum: Immunogenicity of Alum-Adsorbed Clinical-Grade TBV25–28, a Yeast-Secreted Malaria Transmission-Blocking Vaccine CandidateExperimental Parasitology, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- A Region ofPlasmodium falciparumAntigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking AntibodiesInfection and Immunity, 2000
- Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA AgaroseBio/Technology, 1994
- Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25Memórias do Instituto Oswaldo Cruz, 1992
- Malaria transmission-blocking vaccinesTrends in Biotechnology, 1992
- Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.The Journal of Experimental Medicine, 1991
- Induction of Plasmodium falciparum Transmission-blocking Antibodies by Recombinant Vaccinia VirusScience, 1991
- A vaccine candidate from the sexual stage of human malaria that contains EGF-like domainsNature, 1988